Ischemic Stroke. Cerebellar stroke syndrome
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Including 37 patients who will receive 30 mg of saffron capsules from Duralife -Faran Chemi Pharmaceutical Company (15 mg twice a day) for 30 da
Sponsors
Ghoum University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: Patients with a definitive diagnosis of acute ischemic stroke Age between 18 and 80 years Glasgow Coma Scale (GCS) score of 15 National Institutes of Health Stroke Scale (NIHSS) score less than 15 Absence of coagulation or platelet disorders at admission Obtaining informed consent from the patient or their legal guardian
Exclusion criteria
Exclusion criteria: History of previous stroke or cognitive disorders and Alzheimer's disease Receiving thrombolytic therapy (rtPA) for the current stroke Known hypersensitivity to saffron Suffering from advanced liver or kidney diseases Occurrence of fever or seizures at the time of initial admission
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Level of consciousness. Timepoint: arrival; hospitalization time; while receiving medication. Method of measurement: Glasgow coma scale. | — |
Secondary
| Measure | Time frame |
|---|---|
| Length of hospitalization. Timepoint: The time of the patient's discharge from the hospital. Method of measurement: National Institutes Of Health Stroke Scale. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactZahra Mohammadi
Ghoum University of Medical Sciences
Outcome results
None listed